IP Library Granted Patent US 8,076,134
Granted Patent B2
US 8,076,134 · App. 11/765,720 · Granted Dec 13, 2011

CD4+CD25− T cells and Tr1-like regulatory T cells

Assignee: Argos Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,134
App. No.
11/765,720
Granted
Dec 13, 2011
Kind
B2
Abstract

The invention provides CD4 + CD25 − T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.

Claims (7)

1. A method of suppressing the proliferation of human CD4 + T cells ex vivo or in vivo comprising the steps of:

(a) isolating CD4 + CD25 + T cells from human peripheral blood;

(b) anergizing human CD4 + CD25 − T cells by contacting the CD4 + CD25 − T cells ex vivo with an anergic state inducing agent consisting of CD4 + CD25 + T cells and an activation stimulus, wherein the activation stimulus is selected from the group consisting of (i) and (ii), wherein (i) is a combination of plate-bound anti-CD3 and soluble anti-CD28 antibodies; and (ii) are allogeneic mature dendritic cells, whereby Tr-1 like regulatory cells are produced; and

(c) suppressing the proliferation of said CD4+ T cells by (i) introducing said Tr-1 like regulatory cells to a composition comprising said CD4+ T cells ex vivo or (ii) administering said Tr-1 like regulatory cells to a human subject in vivo.

2. The method of claim 1 , wherein step (b) of the method of producing said Tr-1 like regulatory cells comprises co-culturing the CD4 + CD25 31 cells with CD4 + CD25 + cells ex vivo.

3. The method of claim 1 , wherein said Tr1-like regulatory cells produce IL-10.

4. The method of claim 3 , wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4 + T cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
Priority Claims (1)
EP 02018025 · Aug 12, 2002 · regional
Continuity (3)
Division 10618134 · Jul 11, 2003
Provisional Application 60419177 · Oct 17, 2002
Related Publication 20070258959A1 · Nov 8, 2007